Fenfluramine is known to produce increased heart rate, a physical effect. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Increased heart rate, clinically termed tachycardia when exceeding 100 beats per minute at rest, manifests as a heightened awareness of one's own cardiac rhythm. At lower intensities, users may simply notice their pulse feels slightly faster than baseline—a faint thumping sensation in the chest or a mild warmth spreading through the torso. At higher intensities, the heartbeat becomes impossible to ignore: a powerful, rapid drumming that can be felt in the throat, wrists, and behind the eyes, sometimes accompanied by visible pulsation of veins and a sensation of the heart "trying to escape" the ribcage.
The intensity of this effect follows a clear dose-dependent curve. At threshold doses of stimulants or psychedelics, heart rate may increase by only 5-15 BPM above baseline—barely perceptible without deliberately checking one's pulse. At moderate doses, increases of 20-40 BPM become noticeable during both activity and rest, often accompanied by a subtle chest tightness. At high doses or during combinations, heart rate can spike to 140-180+ BPM, producing significant discomfort, breathlessness, and anxiety that may trigger panic responses that further compound the tachycardia.
Several distinct subtypes exist. Stimulant-induced tachycardia tends to feel "electric" and buzzing, as if the heart is running at high RPM but smoothly. Psychedelic tachycardia is often intermittent and closely tied to emotional state—surges of awe or anxiety produce momentary spikes. Cannabinoid-induced increases feel more diffuse and are frequently accompanied by postural hypotension. Dissociative tachycardia is often less consciously noticed due to the analgesic and detaching properties of these substances, making it particularly insidious.
Pharmacologically, increased heart rate results from several mechanisms: direct sympathomimetic activation (as with amphetamines and cocaine, which increase catecholamine release), vagal nerve suppression (as with anticholinergic compounds), peripheral vasodilation triggering baroreceptor-mediated compensatory tachycardia (as with cannabis and some psychedelics), or direct agonism at cardiac beta-adrenergic receptors. Serotonergic compounds can also produce tachycardia via 5-HT2A and 5-HT2B receptor activation.
This effect is most prominently associated with stimulants (amphetamines, cocaine, MDMA, caffeine), but it is also common with psychedelics (LSD, psilocybin, mescaline), cannabinoids (THC), dissociatives (PCP, ketamine at higher doses), and empathogens. Essentially, any substance that activates the sympathetic nervous system or suppresses parasympathetic tone can produce it.
From a harm reduction perspective, increased heart rate becomes dangerous when sustained at very high levels, in individuals with pre-existing cardiac conditions, or when combined with other cardiotoxic substances. The combination of stimulants with MAOIs or other stimulants poses particular risk for hypertensive crisis. Users experiencing tachycardia should avoid further stimulant intake, remain hydrated, practice slow breathing techniques, and seek medical attention if heart rate exceeds 150 BPM at rest or is accompanied by chest pain, irregular rhythm, or difficulty breathing.
Increased heart rate can manifest at varying intensities depending on the dose of Fenfluramine and individual sensitivity. The following levels describe the typical progression of this effect.
A subtle awareness of one's heartbeat, only noticeable when paying attention. Heart rate increased by 5-15 BPM above baseline.
Heart rate is clearly elevated and noticeable during rest. Mild warmth in the chest. Increase of 15-30 BPM.
A pronounced, forceful heartbeat felt in the chest, neck, and wrists. Accompanied by mild breathlessness. Increase of 30-50 BPM.
Rapid, pounding heartbeat that dominates body awareness. Visible pulsation in veins. Accompanied by anxiety and chest tightness. 50-70+ BPM above baseline.
An extremely rapid, forceful heartbeat exceeding 150 BPM at rest. May feel chaotic or irregular. Accompanied by significant distress, breathlessness, and potential medical danger.
Fenfluramine's defining mechanism is substrate-type serotonin release. Like MDMA and other serotonin releasing agents, fenfluramine enters presynaptic serotonergic terminals through the serotonin transporter (SERT) -- it is a substrate for the transporter, not a blocker. Once inside the terminal, it does two things simultaneously:
Reverses SERT function. The transporter normally pumps serotonin into the cell from the synapse. Fenfluramine forces it to work in reverse, causing carrier-mediated efflux of serotonin into the synaptic cleft. This is non-exocytotic release -- it bypasses the normal vesicle-fusion machinery entirely.
Disrupts vesicular storage. Fenfluramine is also a substrate for the vesicular monoamine transporter (VMAT), which normally packages serotonin into synaptic vesicles for regulated release. By interfering with VMAT, fenfluramine dumps cytoplasmic serotonin out of its vesicular compartments, increasing the pool of free serotonin available for reverse transport through SERT.
The result is a massive, sustained increase in extracellular serotonin concentrations -- conceptually similar to MDMA, but with a critical difference in selectivity. Fenfluramine releases serotonin with far greater potency than it releases dopamine or norepinephrine. This serotonergic selectivity explains why fenfluramine feels nothing like classical amphetamine: it produces sedation, appetite suppression, and anxiolysis rather than the euphoric drive and focus associated with dopaminergic stimulation.
Fenfluramine undergoes extensive hepatic N-deethylation (primarily via CYP1A2, CYP2B6, and CYP2D6) to form norfenfluramine, which is pharmacologically active and reaches approximately half the plasma concentration of the parent compound at steady state. Norfenfluramine has its own receptor profile that differs markedly from fenfluramine itself:
5-HT2B receptor: High-affinity full agonist (Ki = 27 nM for d-norfenfluramine, 65 nM for l-norfenfluramine). This is the receptor responsible for cardiac valvulopathy -- 5-HT2B activation on valvular interstitial cells drives pathological cell proliferation and fibrotic tissue deposition. The potency at this receptor is striking: norfenfluramine is among the most potent known 5-HT2B agonists, comparable to ergot alkaloids associated with the same valvular pathology.
5-HT2C receptor: High-affinity agonist (Ki = 56 nM for d-norfenfluramine, 99 nM for l-norfenfluramine). This is the receptor responsible for appetite suppression -- 5-HT2C agonism in the hypothalamus reduces food intake through activation of POMC (pro-opiomelanocortin) neurons in the arcuate nucleus.
5-HT2A receptor: Moderate-affinity agonist. This is the receptor responsible for the hallucinogenic effects observed at high doses -- the same receptor through which LSD, psilocybin, and other classical psychedelics produce their characteristic perceptual distortions.
Fenfluramine has several secondary pharmacological actions that contribute to its complex profile:
Sigma-1 receptor positive modulation: Sub-micromolar affinity. The sigma-1 receptor is increasingly recognized as important in seizure control, which may contribute to fenfluramine's anticonvulsant efficacy beyond its serotonergic actions.
GABAergic enhancement: Fenfluramine enhances GABAergic neurotransmission and has been shown to restore dendritic arborization of GABAergic neurons in animal models of Dravet syndrome. This mechanism is particularly relevant to its use in epilepsy.
Norepinephrine release: Fenfluramine is also a norepinephrine releasing agent, though with significantly lower potency than for serotonin.
Neuroendocrine effects: Increases prolactin levels, stimulates ACTH release via POMC neurons, and activates oxytocinergic and vasopressinergic neurotransmission.
Fenfluramine is well absorbed orally with a bioavailability of 68-83%, unaffected by food. It distributes extensively into tissues with a large volume of distribution (11.9 L/kg), reflecting significant tissue binding and accumulation. Peak plasma concentrations occur at 3 hours after a single dose and 4-5 hours at steady state.
The elimination half-life is notably long: 13-30 hours for the parent compound (mean approximately 20 hours), with the d-enantiomer clearing faster (~19 hours) than the l-enantiomer (~25 hours). The active metabolite norfenfluramine has an even longer half-life -- d-norfenfluramine ~34 hours, l-norfenfluramine ~50 hours. This means pharmacological activity persists well beyond the perceived peak of subjective effects.
Steady state is achieved within 4-8 days of regular dosing. Protein binding is approximately 40-50%.
CYP2D6 is a critical metabolic bottleneck. Drugs that inhibit CYP2D6 (including fluoxetine, paroxetine, and quinidine) significantly increase fenfluramine plasma concentrations, creating a dangerous pharmacokinetic interaction on top of the pharmacodynamic serotonin syndrome risk.
Fenfluramine can be administered via oral. The route of administration can influence both the onset and intensity of increased heart rate.
The intensity of increased heart rate depends heavily on the dose of Fenfluramine. Effects like increased heart rate are typically reported at common to strong doses. Below is the full dosage chart for Fenfluramine.
Warning
Sustained heart rates above 150 BPM can strain the cardiovascular system and may trigger arrhythmias in susceptible individuals. This effect is particularly dangerous when combining stimulants, in people with pre-existing heart conditions, or with substances that prolong the QT interval. Seek medical attention for chest pain, irregular rhythm, or sustained extreme tachycardia.
Yes. Increased heart rate is a documented physical effect of Fenfluramine. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Effects like increased heart rate are typically reported at common doses and above. A common oral dose of Fenfluramine is 60–120 mg.
Other substances documented to produce increased heart rate include Amphetamine, Cocaine, MDMA, Cannabis, Caffeine, and 35 more.
